Insider Selling: Jeffrey Bloss Sells Shares of NCNA

Jeffrey Bloss, the Chief Medical Officer of NCNA, sold shares of the company on June 19, 2026. The transaction was not part of a pre-planned trading program. This insider activity comes as NCNA shares traded at $1.73 on Wednesday.

Insider Buying and Selling at NuCana plc

Jeffrey Bloss, serving as the Chief Medical Officer, sold shares of NCNA on June 19, 2026. The transaction was not executed under a Rule 10b5-1 trading plan, which often indicates it was not pre-scheduled. Earlier in the year, on April 15, 2026, Theresa Margaret Bruce, the Chief Operating Officer, purchased a significant number of shares, reflecting her confidence in the company's prospects.

Other Institutional Activity in NCNA

Several institutional investors have adjusted their positions in NCNA. Glass Jacobson Investment Advisors LLC maintained its holdings at 15,000 shares, valued at approximately $21,000. Citadel Advisors LLC opened a new position with 13,855 shares, worth about $19,536. Similarly, Virtu Financial LLC initiated a stake with 13,433 shares valued at $19,000. Meanwhile, Jane Street Group, LLC, reduced its holdings by 819 shares, ending with 10,511 shares valued at $14,715, marking a 7.2% decrease. Rhumbline Advisers also trimmed its position by 1,187 shares, a 24.2% decrease, leaving them with 3,722 shares valued at $5,245.

Analysts Set New Price Targets

On July 22, 2024, Oppenheimer maintained its 'buy' rating on NCNA, setting a price target of $150. This reflects continued confidence in the company's potential from the analyst community.

Bottom Line

The recent insider sale by Jeffrey Bloss is notable, though it was not part of a planned sale. Investors often watch insider transactions for signals about a company's health. Institutional activity shows mixed movements, with some funds increasing their positions and others reducing. Analysts maintain a positive outlook, as reflected in Oppenheimer's 'buy' rating and $150 price target.